These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25118853)

  • 1. The evaluation and management of refractory neurogenic overactive bladder.
    Kurpad R; Kennelly MJ
    Curr Urol Rep; 2014 Oct; 15(10):444. PubMed ID: 25118853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of refractory OAB in the non-neurogenic patient.
    Wadie BS
    Curr Urol Rep; 2014 Sep; 15(9):438. PubMed ID: 25015301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?
    Zahner PM; Giusto LL; Goldman HB
    Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
    Rachaneni S; Latthe P
    Int Urogynecol J; 2017 Jun; 28(6):805-816. PubMed ID: 28083714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of neuromodulation in patients with neurogenic overactive bladder.
    Lay AH; Das AK
    Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
    Sherif H; Khalil M; Omar R
    Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical and Urodynamic Results of Percutaneous Posterior Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Patients With Parkinson's Disease.
    Kabay S; Canbaz Kabay S; Cetiner M; Mestan E; Sevim M; Ayas S; Ozden H; Ozisik Karaman H
    Urology; 2016 Jan; 87():76-81. PubMed ID: 26436213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of overactive bladder in women].
    Peyronnet B; Rigole H; Damphousse M; Manunta A
    Prog Urol; 2015 Nov; 25(14):877-83. PubMed ID: 26169251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
    Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
    Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
    Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
    Malde S; Fry C; Schurch B; Marcelissen T; Averbeck M; Digesu A; Sahai A
    Neurourol Urodyn; 2018 Jun; 37(S4):S108-S116. PubMed ID: 30133790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
    Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
    Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
    Haab F
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.